GeoCell
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- BioGeometry links AI models with automated drug-discovery experiments
BioGeometry has developed what it calls a “self-evolving microscopic world model,” connecting molecular design, cell-response modeling and automated experiments so results can feed back into the system. The report says the company’s GeoFlow V3 achieved a nearly 20% average hit rate for lead molecules across more than 20 targets and compressed lead-discovery cycles to within three weeks; in a project for a European pharmaceutical company, it reportedly identified multiple molecules meeting multiple requirements in one iteration and shortened delivery by more than 50%. GeoCell models transcriptional responses under different perturbations for target discovery, indication selection and patient stratification. BioGeometry was also reported to have completed an A+ financing round, bringing cumulative Series A funding above $100 million. Most performance figures came from the company, while the financing was not independently confirmed in the report.
MIT科技评论中文 · 🔥 0 - Baiaogeometry Raises A+ Round as A-Series Funding Tops $100M
AI-native biopharmaceutical company Baiaogeometry announced an A+ financing round led by Guoshou Capital, with Shanghai Biopharmaceutical Fund increasing its investment and other firms participating. According to 36氪, the company’s cumulative A-series funding now exceeds US$100 million. The proceeds are earmarked for iterating the GeoFlow molecular-level and GeoCell cell-level world models, expanding high-throughput automated laboratories, and commercializing its proprietary drug pipeline.
36氪快讯 · 🔥 0
Experience and discussion from the community
Share my GeoCell experienceAsk about GeoCell
Nobody has shared their experience with GeoCell yet.